Introduction Adeno-associated virus (AAV)-based gene therapy can initiate host-immune responses to the AAV vector components or the transgenic protein product which could reduce AAV-mediated expression. Data from preclinical studies suggest that corticosteroid treatment may limit these immune responses and improve gene therapy outcomes.
Stuart Bunting合作论文数4Lin Xie合作论文数4
Natalie Fredette合作论文数4Christa Cortesio合作论文数3Hassib Akeefe合作论文数3Vishal Agrawal合作论文数3Peter Colosi合作论文数3Jill R. Woloszynek合作论文数3W. Zhang合作论文数2Katina Ngo合作论文数2Brian Baridon合作论文数2Lening Zhang合作论文数2Taren Bouwman合作论文数BioMarin Pharmaceut Inc2Cheng Su合作论文数2Britta Handyside合作论文数2Sherry Bullens合作论文数2
Veres Gabor合作论文数bluebird bio2
Ryan J. Murphy合作论文数Milton S. Eisenhower Research Center, The Johns Hopkins University Applied Physics Laboratory2Olivia Gorostiza合作论文数2
Sylvia Fong合作论文数California Pacific Medical Center, Cancer Research Institute2Atul Sathe合作论文数1Alexander Giaramita合作论文数1Nicole Galicia合作论文数1Kahsay Gebretsadik合作论文数1Katie Black合作论文数1Bridget Yates合作论文数1Lisa Razon合作论文数1Choong-Ryoul Sihn合作论文数1Katherine Webster合作论文数1S Bullens合作论文数1Amanda R Luu合作论文数1Gouri Yogalingam合作论文数1B. Yates合作论文数1Joseph Chen合作论文数1Su Liu合作论文数1
Choong-ryoul Sihn合作论文数1
Daniel Wendt合作论文数1Crawford Brett E合作论文数1
Sílvia Sisó合作论文数AbbVie1
Gabor Veres合作论文数1st Department of Pediatrics, Semmelweis University;Department of Paediatrics, Medical School, University of Debrecen1Steven Froelich合作论文数Mork Family Department of Chemical Engineering and Materials Science, University of Southern California1
